Trial Profile
First of two global phase III trials of T 89 in patients with angina pectoris due to coronary heart disease
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2011
Price :
$35
*
At a glance
- Drugs T 89 (Primary)
- Indications Angina pectoris
- Focus Adverse reactions; Therapeutic Use
- 23 Nov 2011 Status changed from planning to recruiting based on an ICON media release
- 13 Oct 2011 New trial record